Document is current
Any future updates will be listed below
-
Authors
Gross, Sophia
Ihlow, Jana https://orcid.org/0000-0001-5484-1321
Busack, Leonie
Adamiak, Kacper
Schrezenmeier, Jens
Jesse, Julia
Schwarz, Michaela
Flörcken, Anne
Vuong, Lam Giang
Rieger, Kathrin
Krönke, Jan https://orcid.org/0000-0002-4649-0506
le Coutre, Philipp
Boldt, Vivien
von Brünneck, Ann-Christin
Horst, David
Burmeister, Thomas https://orcid.org/0000-0003-4843-2876
Blau, Igor-Wolfgang
Keller, Ulrich https://orcid.org/0000-0002-8485-1958
Bullinger, Lars https://orcid.org/0000-0002-5890-5510
Westermann, Jörg
- License Information
-
More Information
Article History
Received: 2 June 2024
Revised: 2 September 2024
Accepted: 4 September 2024
First Online: 16 September 2024
Competing interests
: JI: travel support from Medac. AF: honoraria from Pharmaphar; Ipsen; Lilly. JK: honoraria from Janssen, BMS/Celgene, Takeda; Astra Zeneca, Amgen; Sanofi Aventis; Abbvie. PLC: honoraria from Pfizer; Incyte; Novartis. UK: Honoraria from Novartis. LB: honoraria from AbbVie, Amgen, Astellas, BristolMyers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Roche, and Sanofi, as well as research support from Bayer and Jazz Pharmaceuticals. JW: honoraria from Abbvie, Pfizer, Novartis; Jazz Pharmaceuticals, Roche; Astellas; Amgen; Sanofi Aventis; Bristol Myers Squibb, SoBi, Otsuka. The authors declare no competing interests.
: The study is in line with the Declaration of Helsinki and was approved by the local ethics committee of the Charité-Universitätsmedizin Berlin (registration number EA4/026/23). All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all participants.
